Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × INDUSTRY × AML × Clear all

Phase

Status

Terminated 1 Recruiting 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 408 Neoplasms 284 Breast Neoplasms 263 Colorectal Neoplasms 216 Neoplasm Metastasis 173 Ovarian Neoplasms 159 Recurrence 146 Prostatic Neoplasms 138 Lung Neoplasms 138 Pancreatic Neoplasms 132 Squamous Cell Carcinoma of Head and Neck 125 Multiple Myeloma 122 Melanoma 116 Stomach Neoplasms 114 Leukemia, Myeloid, Acute 112 Endometrial Neoplasms 111 Advanced Solid Tumor 104 Triple Negative Breast Neoplasms 92 Advanced Solid Tumors 92 Uterine Cervical Neoplasms 85 Carcinoma, Hepatocellular 85 Lymphoma, Non-Hodgkin 82 Small Cell Lung Carcinoma 73 Lymphoma 71 Carcinoma, Renal Cell 65 Lymphoma, Follicular 63 Solid Tumor 62 Lymphoma, Large B-Cell, Diffuse 62 Leukemia, Lymphocytic, Chronic, B-Cell 62 Esophageal Neoplasms 58

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06731699 2024-12-17

A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS

Chengdu FenDi Pharmaceutical Co., Ltd.

Phase 1 Recruiting

AML

Data powered by HemOnc (CC BY 4.0) Colophon ⚡